A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)

被引：23
|
作者：
Uzzo, Robert
Bex, Axel
Rini, Brian I.
Albiges, Laurence
Suarez, Cristina
Donaldson, Frank
Asakawa, Takashi
Schiff, Christina
Pal, Sumanta K.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[3] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH 44106 USA
[4] Inst Gustave Roussy, Villejuif, France
[5] Vall dHebron Univ Hosp Inst Oncol VHIO, Barcelona, Spain
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[8] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS4598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4598
引用
收藏
页数：5
相关论文
共 50 条
  • [41] ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
    Kwon, Tae Gyun
    Seong, Seo
    Byun, Seok-Soo
    Miyake, Hideaki
    Ueda, Takeshi
    Ye, Dingwei
    Garcia-Donas, Jesus
    Gross-Goupll, Marine
    Hutson, Thomas E.
    DeBenedetto, Robert
    Hariharan, Subramanian
    Lee, Min Young
    Linke, Rolf Gerhard
    Tsuji, Fumito
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
    Trojan, J.
    Chow, P.
    Chen, M.
    Cheng, A-L
    Kaseb, A.
    Kudo, M.
    Lee, H. C.
    Yopp, A.
    Zhou, J.
    Wang, L.
    Wen, X.
    Heo, J.
    Tak, W-Y
    Nakamura, S.
    Numata, K.
    Uguen, T.
    Hsieh, D.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Qin, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 239
  • [43] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
    Escudier, Bernard J.
    Powles, Thomas
    Motzer, Robert J.
    Olencki, Thomas
    Aren, Osvaldo Rudy
    Oudard, Stephane
    Bracarda, Sergio
    Tomczak, Piotr
    Castellano, Daniel E.
    Appleman, Leonard Joseph
    Drabkin, Harry A.
    Vaena, Daniel A.
    Milwee, Steven
    Youkstetter, Jillian
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
    Exposito, M. J. Jimenez
    Akce, M.
    Alvarez, J. L. M.
    Assenat, E.
    Balart, L. A.
    Baron, A. D.
    Decaens, T.
    Heurgue-Berlot, A.
    Martin, A. O.
    Paik, S. W.
    Poulart, V.
    Sehbai, A. S.
    Shimada, M.
    Takemura, N.
    Yoon, J-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
    Exposito, M. J. Jimenez
    Akce, M.
    Montero Alvarez, J. L.
    Assenat, E.
    Balart, L. A.
    Baron, A. D.
    Decaens, T.
    Heurgue-Berlot, A.
    Martin, A. O.
    Paik, S. W.
    Poulart, V.
    Sehbai, A. S.
    Takemura, N.
    Yoon, J-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] Molecular correlates of differential response to Atezolizumab plus /- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients
    McDermott, David
    Huseni, Mahrukh
    Rini, Brian
    Motzer, Robert
    Atkins, Michael
    Escudier, Berard
    Nickles, Dorothee
    Boyd, Zach
    Sampath, Shruthi
    Doss, Jennifer
    Leng, Ning
    Schiff, Christina
    Chen, Daniel S.
    Fine, Gregg
    Powles, Thomas
    Hegde, Priti S.
    CANCER RESEARCH, 2017, 77
  • [47] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
    Rischin, Danny
    Fury, Matthew G.
    Lowy, Israel
    Stankevich, Elizabeth
    Han, Hyunsil
    Porceddu, Sandro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection
    Liu, L-X.
    Peng, T.
    Liu, C.
    Wang, J.
    Zhu, G.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1444 - S1444
  • [50] Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
    Motzer, R. J.
    Russo, P.
    Gruenwald, V.
    Tomita, Y.
    Zurawski, B.
    Parikh, O. A.
    Buti, S.
    Barthelemy, P.
    Goh, J. C. H.
    Ye, D.
    Lingua, A.
    Lattouf, J-B.
    Escudier, B.
    George, S.
    Shuch, B.
    Simsek, B.
    Spiridigliozzi, J.
    Chudnovsky, A.
    Bex, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1430
12345